ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development

EPI-7386 was safe and well-tolerated at all dose levels and schedules tested with plasma target concentrations achieved and clinically important efficacy signals Conference Call and Webcast Today at 5:00 p.m. ET SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 27, 2022...

Click to view original post